I recently blogged about Insulin Degludec. A few more papers have been published since then.
The Lancet has published some open label, phase 3, funded-by-the-manufacturer (Novo Nordisk) papers on the use of insulin degludec in Type 1 and Type 2 diabetes [1,2].
Both were 1 year trials randomised to degludec or glargine. In type 2 diabetes the rates of mild to moderate, daytime or nocturnal hypoglycaemia seemed to be lower in the degludec patients but not the rate of severe hypoglycaemia. [2]
In Type 1 diabetes there results were similar for both glargine or degludec but there was reduction in 'confirmed nocturnal hypoglycaemia'. Again there were no differences in severe hypoglycaemia. [1]
1. Heller S, Buse J, Fisher M, Garg S, Marre M, Merker L, Renard E, Russell-Jones D, Philotheou A, Francisco AMO, Pei H, Bode B. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012 Apr;379(9825):1489–1497. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22521071
2. Garber AJ, King AB, Del Prato S, Sreenan S, Balci MK, Muñoz-Torres M, Rosenstock J, Endahl LA, Francisco AMO, Hollander P. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012 Apr;379(9825):1498–1507. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22521072
The Lancet has published some open label, phase 3, funded-by-the-manufacturer (Novo Nordisk) papers on the use of insulin degludec in Type 1 and Type 2 diabetes [1,2].
Both were 1 year trials randomised to degludec or glargine. In type 2 diabetes the rates of mild to moderate, daytime or nocturnal hypoglycaemia seemed to be lower in the degludec patients but not the rate of severe hypoglycaemia. [2]
In Type 1 diabetes there results were similar for both glargine or degludec but there was reduction in 'confirmed nocturnal hypoglycaemia'. Again there were no differences in severe hypoglycaemia. [1]
1. Heller S, Buse J, Fisher M, Garg S, Marre M, Merker L, Renard E, Russell-Jones D, Philotheou A, Francisco AMO, Pei H, Bode B. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012 Apr;379(9825):1489–1497. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22521071
2. Garber AJ, King AB, Del Prato S, Sreenan S, Balci MK, Muñoz-Torres M, Rosenstock J, Endahl LA, Francisco AMO, Hollander P. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012 Apr;379(9825):1498–1507. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22521072
No comments:
Post a Comment